BiotechTube

Berinert® (C1 Esterase Inhibitor)

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Includes: Hereditary Angioedema

Conditions

Includes: Hereditary Angioedema

Trial Timeline

Apr 1, 2010 → Apr 1, 2014

NCT ID
NCT01108848

About Berinert® (C1 Esterase Inhibitor)

Berinert® (C1 Esterase Inhibitor) is a pre-clinical stage product being developed by CSL for Includes: Hereditary Angioedema. The current trial status is completed. This product is registered under clinical trial identifier NCT01108848. Target conditions include Includes: Hereditary Angioedema.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01108848Pre-clinicalCompleted

Other Products from CSL

IgPro10Approved
84
four factor prothrombin complex concentrateApproved
84
Prothrombin complex concentrate (Human) + Fresh frozen plasma (FFP)Approved
84
IgPro10Approved
84
Blood coagulation Factor VIII and vWF, humanApproved
84